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Abstract
Cutaneous melanoma is the most aggressive skin cancer; it is highly metastatic and responds poorly to current
therapies. The expression of platelet-derived growth factor receptors (PDGF-Rs) is reported to be reduced in meta-
static melanoma compared with benign nevi or normal skin; we then hypothesized that PDGF-Rα may control
growth of melanoma cells. We show here that melanoma cells overexpressing PDGF-Rα respond to serum with
a significantly lower proliferation compared with that of controls. Apoptosis, cell cycle arrest, pRb dephosphory-
lation, and DNA synthesis inhibition were also observed in cells overexpressing PDGF-Rα. Proliferation was res-
cued by PDGF-Rα inhibitors, allowing to exclude nonspecific toxic effects and indicating that PDGF-Rα mediates
autocrine antiproliferation signals in melanoma cells. Accordingly, PDGF-Rα was found to mediate staurosporine
cytotoxicity. A protein array–based analysis of the mitogen-activated protein kinase pathway revealed that mela-
noma cells overexpressing PDGF-Rα show a strong reduction of c-Jun phosphorylated in serine 63 and of protein
phosphatase 2A/Bα and a marked increase of p38γ, mitogen-activated protein kinase kinase 3, and signal regulatory
protein α1 protein expression. In a mouse model of primary melanoma growth, infection with the Ad-vector over-
expressing PDGF-Rα reached a significant 70% inhibition of primary melanoma growth (P < .001) and a similar inhi-
bition of tumor angiogenesis. All together, these data demonstrate that PDGF-Rα strongly impairs melanoma growth
likely through autocrine mechanisms and indicate a novel endogenous mechanism involved in melanoma control.
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Introduction
Platelet-derived growth factor (PDGF) family members mediate
several different effects, including the control of development, tissue
repair, wound healing, atherosclerosis, stem cells’ recruitment, and
tumor growth [1,2]. The PDGF family consists of five isoforms
(PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD, and PDGF-AB),
showing different binding specificity for PDGF-Rα, PDGF-Rβ,
and PDGF-Rαβ [3]. PDGF-Rα and PDGF-Rβ, although sharing
evolutionary relationships, have distinct ligand specificity and func-
tions [4,5]. PDGF-Rβ induces cell proliferation and migration in
different cell types [4–6], whereas role of PDGF-Rα is more contro-
versial, with proproliferative or antiproliferative effects in different
cell types [7–12]. PDGF-Rα expression has been investigated in
different pathologic conditions; for instance, autoantibodies activat-
ing PDGF-Rα play a key role in scleroderma and systemic sclerosis
and in multiple sclerosis lesions. Hedgehog pathway mutations may
cause basal cell carcinoma, likely through increased expression of
PDGF-Rα, and activating mutations of PDGF-Rα gene were iden-
tified in gastrointestinal tumors.
Melanoma accounts for approximately 4% of skin cancers but
causes approximately 80% of skin cancer deaths. Skin melanoma is
therefore one of the most aggressive tumors in humans, and a hun-
dred thousand new melanoma cases are reported every year in west-
ern countries. Factors influencing melanoma development include
excessive exposure to sunlight, skin type, and genetic predisposition.
The complex genetic network controlling melanoma growth and pro-
gression has been largely investigated, indicating several effectors
involved such as neuroblastoma RAS (NRAS), BRAF, phosphatidyl-
inositol 3-kinase (PI3-K), mitogen-activated protein kinase (MAPK)
pathway, and B-cell CLL/lymphoma 2 [13]. Platelet-derived growth
factor receptors act through MAPKs, and the expression of PDGF re-
ceptors has been found to be decreased in metastatic melanoma com-
pared with those in controls [14], explaining at least in part why
specific inhibitors of these receptors have not shown clinical benefits
in melanoma treatments [15]. This also suggests that loss of PDGF
receptors may represent a way to select more aggressive clones sustain-
ing melanoma progression. Hence, low PDGF-Rα levels may under-
lie, at least in part, melanoma growth with escape from growth/
apoptosis control. Conversely, overexpression of such receptor may
be associated with melanoma inhibition. This hypothesis is supported
by previously published data reporting that PDGF-Rα mediates
strong antiproliferative and antichemotaxis effects on vascular smooth
muscle cells and endothelial cells [9,10,12,16]. We therefore investi-
gated autocrine effects of PDGF-Rα expression in human melanoma
cells and show in the present study that PDGF-Rα overexpression
markedly inhibits melanoma growth, both in vitro and in vivo.
Materials and Methods
Cell Cultures
Human metastatic melanoma cell lines used were SK-MEL-110
[17] and A375-S2, which were from the American Type Culture Col-
lection (ATCC, Manassas, VA), and 397 MEL, which were kindly
provided by Dr S. D’Atri [18]. SK-MEL-110 and A375-S2 were
grown in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone,
South Logan, UT), 10% fetal calf serum (FCS; Hyclone). 397 MEL
were grown in RPMI 1640 (Sigma-Aldrich, Milan, Italy) and 10%
FCS (Hyclone). B16F10 mouse melanoma cells were from the ATCC
and were grown in DMEM (Hyclone) and 10% FCS (Hyclone). All
media were completed by the addition of glutamine and penicillin-
streptomycin (Gibco, Carlsbad, CA). Cells were grown at 37°C with
5% CO2.
Expression of PDGF-Rα in Human Biopsies
Data sets of the gene expression levels from Affymetrix data ob-
tained from biopsies of human melanoma patients were investigated
at the GEO database site (http://www.ncbi.nlm.nih.gov/sites/entrez),
namely, data sets GDS1375, GDS1989, GDS2200, and GDS1965.
The expression levels of PDGF-Rα and PDGF-Rβ, indicated as rank
values, were collected and averaged from all available data points,
namely, 17 normal skin biopsies, 22 nevi, and 52 melanoma biopsies.
Cells’ Transfection
Cells were transfected with a plasmid coding for human PDGF-
Rα (PDGF-Rα) or a dominant-negative form of human PDGF-Rα
(DN-PDGF-Rα; gifts from Dr C.H. Heldin, Sweden) or pcDNA3
empty vector (Invitrogen, Carlsbad, CA). Cells were cotransfected with
pEGFP-N1 (Clontech, Inc, Mountain View, CA) reporter vector (mo-
lar ratio, 3:1). Transfection was performed with Lipofectamine PLUS
reagent (Invitrogen) as previously reported [12]. The transfection me-
dium was then replaced with medium ± 10% FCS. Transfection effi-
ciency was checked by green fluorescence and reached 40% in all cases.
Proliferation Assay
SK-MEL-110, A375-S2, and 397 MEL were transfected with
PDGF-Rα, DN-PDGF-Rα, or pcDNA3 and were allowed to grow
for 24, 48, and 72 hours in medium ± 10% FCS [12]. Cells were then
harvested and counted. Neutralizing antibody anti–human PDGF-AA
(1 ng/ml; R&D Systems, Minneapolis, MN), soluble recombinant
mouse PDGF-Rα/Fc chimera (0.08 μg/ml; R&D Systems), caspase
3 inhibitor (50 μM, z-DEVD-FMK; R&D Systems), or staurosporine
(50 nM; Calbiochem, San Diego, CA) were also used.
Procaspase 3 and PDGF-Rα Protein Expression
in SK-MEL-110
SK-MEL-110 transfected with PDGF-Rα or pcDNA3 were
grown in 10% FCS with or without staurosporine (50 nM). Cells
were then lysed. Proteins were analyzed by SDS-PAGE and were trans-
ferred to nitrocellulose. Western blot analysis was carried out with
anti–procaspase 3 (sc-7148; Santa Cruz Biotechnology, Inc, Santa Cruz,
CA), anti–PDGF-Rα (sc-431; Santa Cruz Biotechnology), and anti–β-
actin (clone ac-15, Product No. 5441; Sigma-Aldrich) antibodies.
Bands’ detection was achieved by horseradish peroxidase–conjugated
secondary antibody (Pierce, Inc, Rockford, IL) and enhanced chemilu-
minescence detection system (Amersham Pharmacia Biotech, GE
Healthcare Europe GmbH, Milan, Italy) and were quantified with a
calibrated imaging densitometer (GS 710; Bio-Rad, Hercules, CA).
TUNEL Assays
SK-MEL-110 (8 × 104) were seeded onto glass coverslips. The fol-
lowing day, cells were transfected with PDGF-Rα or pcDNA3 empty
vector. After 24 hours, cells were fixed, permeabilized, and incubated
with a TUNEL reaction mixture (Boehringer Mannheim, Corp,
Gaithersburg, MD) for cell death in situ detection. After washing, cells
were incubated with Hoechst solution. Hoechst- and TUNEL-positive
nuclei were visualized on a fluorescence microscope (Axioplan; Carl
Zeiss, Milan, Italy).
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Construction of Adenoviral Vectors
A recombinant adenoviral vector expressing EGFP and human
PDGF-Rα (GenBank Accession No. NM_006206; AdCMV.PDGF-
Rα) was generated using the Ad-Easy system [19]. An adenoviral
vector expressing EGFP alone (AdCMV.EGFP) was also generated
as control. Viral titers were estimated by serial dilution on human em-
bryonic kidney 293 cells (ATCC No. CRL-1573) and were expressed
as plaque-forming units per milliliter (PFU/ml). Viral stocks did not
show replication-competent adenovirus particles, as tested on human
lung adenocarcinoma A549 cells (ATCC No. CCL-185). Human SK-
MEL-110 or mouse B16F10 melanoma cells were transduced at 10,
30, and 100 multiplicity of infection (MOI) with recombinant
AdCMV.PDGF-Rα or AdCMV.EGFP resuspended in serum-free
DMEM and were incubated for 90 minutes at 37°C and 5% CO2.
Medium was then replaced with DMEM + 10% FCS for 24, 48,
and 72 hours. Cells were counted with a hemacytometer and used
for the following in vitro and in vivo experiments. The infection effi-
ciency reached at least 65% in all cases as assessed by FACS analysis.
Flow Cytometry Analysis
Floating and attached PDGF-Rα– or pcDNA3–transfected cells
were harvested, fixed, and treated with RNAse (1 mg/ml) and
propidium iodide (PI, 5 μg/ml; Sigma-Aldrich). Analysis of sub-G1
population was carried out on a Coulter Epics XL flow cytometer
(Beckman Coulter, Fullerton, CA) and analyzed with WinMDI soft-
ware ( Joseph Trotter; Scripps Research Institute, La Jolla, CA). SK-
MEL-110 were also infected with AdCMV.PDGF-Rα or AdCMV.
EGFP, incubated for 10 minutes with 20 μM bromodeoxyuridine
(BrdU; Sigma), and fixed. Cell cycle analysis was performed by com-
bined BrdU and PI staining using a Becton Dickinson flow cytometer
(Franklin Lakes, NJ) and Cell Quest software (Becton Dickinson) for
quantification of BrdU-positive cells [20,21].
Analysis of pRb Phosphorylation Status
After a 48-hour culture, infected cells were lysed [20], and protein
concentration was assayed by bicinchoninic acid (BCA) protein assay
kit (Pierce). Proteins underwent SDS-PAGE and were transferred
onto nitrocellulose. The antibodies used for the detection were anti-
tubulin (CP06; Oncogene, Cambridge, MA), anti-pRb (G3-245; BD
PharMingen, Becton, Dickinson), anti–hypophosphorylated-pRb
(G99-549; BD PharMingen), and anti–PDGF-Rα (sc-431; Santa
Cruz Biotechnology).
Protein Microarray for MAPK Pathway Analysis
SK-MEL-110 were infected with AdCMV.EGFP or AdCMV.
PDGF-Rα. After 24 hours of starvation, cells were lysed according
to the data sheet of the Panorama Antibody Microarray for MAPK
and PKC pathways (Sigma). Extracts from controls and treated sam-
ples (1 mg/ml) were labeled using Cy3 and Cy5 dyes, respectively,
(PA23001 and PA25001; GE Healthcare, Waukesha, WI). Replicates
were made with inverted staining (Cy5 and Cy3, respectively). Free
dye excess was eliminated by centrifuging at 4000 rpm in SigmaSpin
columns (Sigma-Aldrich). Simultaneous expression analysis of mem-
bers of the MAPK and PKC pathway was then achieved with the
Panorama Antibody Microarray Kit (Sigma). This array contains
77 different antibodies against members of the MAPK family and
several antibodies against housekeeping proteins, each spotted in du-
plicate on nitrocellulose-coated glass slides. Only samples with a dye-
to-protein molar ratio greater than 2 were applied to the antibody
microarray, according to the manufacturer. The hybridized microarray
slides were scanned on a ScanArray Gx Microarray Analysis System
(Perkin Elmer, Wellesley, MA) with 543 and 633 nm lasers. Data were
normalized according to the Lowess method [22] and the manufac-
turer’s recommendation. Ratios of treated versus control samples for
each spot were computed to estimate the relative fold excess. Modula-
tions lower than two-fold or higher than three-fold versus control were
then validated by Western blot analysis.
Ex Vivo and In Vivo Primary Melanoma Growth Assay
Ex vivo and in vivo mouse primary melanoma growth assays were
carried out as previously reported with modifications [23], accord-
ing to an accepted animal study protocol. Adult male C57BL/6 mice
( Jackson Laboratories, Bar Harbor, ME) were anesthetized by an in-
traperitoneal injection of 2.5% Avertin (Sigma-Aldrich); in ex vivo
experiments, mice (17 controls and 17 treated, in three independent
experiments) received subcutaneous inoculation in the dorsal skin of
1 × 106 B16F10 cells previously (24 hours) infected with 100 MOI
AdCMV.PDGF-Rα or AdCMV.EGFP, dissolved in 50 μl of PBS.
For in vivo experiments, 1 × 106 uninfected B16F10 cells were injected
in the dorsal skin, and 4 days later, mice (14 controls and 14 treated, in
two independent experiments) were treated with AdCMV.PDGF-Rα
or AdCMV.EGFP inoculation (4.5 × 108 PFU/ml each). Three virus in-
jections (333 μl each) were carried out around the tumor site. Tumors
were removed 2 weeks after cell inoculation, weighed, fixed in 4% for-
malin for 48 hours, and embedded in paraffin. Five-micrometer-thick
sections from each sample were obtained and evaluated with a
photomicroscope software (Olympus, Tokyo, Japan); digital images
were obtained with a high-definition camera with a charge-coupled
device. Capillaries were identified with antibodies anti-CD31 (mono-
clonal antibody 1A10; Dako, Milan, Italy) and anti–factor VIII–related
antigen (FVIII-RA, M0616; Dako). Immunodetection was performed
with a secondary antibody conjugated with alkaline phosphatase
(Dako) and Fast Red as chromogen, followed by hematoxylin counter-
staining. Primary antibody was omitted in controls.
Statistical Analysis
All experiments were performed at least three times in duplicates.
Standard one-tail Student’s t test was carried out to evaluate the sta-
tistical significance; P < .05 was considered to be significant.
Results
Expression of PDGF-Rα Is Reduced in Melanoma Compared
with Normal Skin
Previous immunohistochemistry analyses, carried out onto tissue
microarrays, show that the expression of PDGF-Rα and β is reduced
in melanoma cells compared with benign nevi [14], whereas other
studies indicate opposing evidence [24]. Expression of PDGF re-
ceptors onto melanoma cells membrane may or may not reflect the
biology of such tumor and may also depend on the experimental
conditions under evaluation. We analyzed gene expression profiles
from four independent studies [25–28] in a total of 55 human mel-
anoma biopsies, 22 benign nevi biopsies, and 17 normal skin biop-
sies. The analysis revealed 36% reduction of the average level of
PDGF-Rα gene expression, in melanoma biopsies compared with
normal skin (P < .01), whereas PDGF-Rβ gene expression did not
show a significant change (Figure 1). These data, along with results
reported in the literature, provided a rationale to suggest that, at least
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in a significant number of cases, the metastatic potential in melanoma
cells may increase in cells showing reduced PDGF-Rα expression,
whereas melanoma inhibition may associate with overexpression of
such receptor. So far, the action of PDGF-Rs on melanoma cells
has been poorly investigated. We therefore investigated the effect
of PDGF-Rα and of its ligand PDGF-AA on melanoma growth.
PDGF-Rα Overexpression Inhibits Melanoma
Cells Proliferation
Human recombinant PDGF-AA unexpectedly was found to
strongly inhibit FCS-induced proliferation of metastatic melanoma
cells (SK-MEL-110) in a dose-dependent manner (Figure 2A).
PDGF-AA binds PDGF-Rα only [3]; therefore, we hypothesized
again that this receptor may exert a negative control in melanoma
growth. SK-MEL-110 were transfected with an expression plasmid
encoding human PDGF-Rα or with a pcDNA3 empty vector as con-
trol. Up to three-fold overexpression of PDGF-Rα, by Western blot
analysis, was observed at 24 and 48 hours (Figure 2E ). Transfected
melanoma cells proliferated significantly less than controls (trans-
fected with the empty pcDNA3 vector), at 24 and 48 hours, both
in the presence and in the absence of FCS (Figure 2, B and C , re-
spectively). Such antiproliferation effect is reported as representative
Figure 2. Inhibition of SK-MEL-110 growth. (A) Melanoma cell proliferation is inhibited by PDGF-AA after a 48-hour treatment in 10% FCS
(*P < .05 vs FCS alone): 100% = 11 × 105 cells per well. (B and C) Proliferation (with or without 10% FCS, respectively) of SK-MEL-110
untransfected (WT) or transfected with PDGF-Rα or with pcDNA3 empty vector. Proliferation of cells overexpressing PDGF-Rα was
significantly inhibited at 24 and 48 hours of culture. Bars indicate mean ± SD of three experiments. Data are percent versus number
of cells seeded (8 × 104 cells per well). *P < .05 versus pcDNA3-transfected cells. (D) Representative fields of the experiment depicted
in panel B at 48 hours. (E) Inverse relation between proliferation and PDGF-Rα expression. Quantification is reported for PDGF-Rα protein
expression by densitometry (left-hand axis) and proliferation (right-hand axis). Data are mean ± SD of three experiments and are ex-
pressed as fold induction versus control. *P < .05 versus time 0. (F) At 24 hours, 10% FCS–induced proliferation of human metastatic
melanoma cells (SK-MEL-110, A375-S2, and 397 MEL) untransfected (WT) or transfected with PDGF-Rα or with pcDNA3 empty vector.
Proliferation was significantly inhibited in cells overexpressing PDGF-Rα. Data are mean ± SD from three experiments. *P < .05 versus
pcDNA3-transfected cells (100% = 326 × 103, 100 × 103, 318 × 103 for SK-MEL-110, 397 MEL, and A375-S2, respectively).
Figure 1. Gene expression level of PDGF-Rα and PDGF-Rβ in hu-
man biopsies. Gene expression profiles from healthy skin biop-
sies, benign nevi biopsies, or malignant melanoma biopsies (i.e.,
collected and pooled fromdata sets GDS1375, GDS1989, GDS2200,
GDS1965) were retrieved at GEO database site (http://www.ncbi.
nlm.nih.gov/sites/entrez). Rank values were collected and averaged.
PDGF-Rα gene expression is reduced by 36% in melanoma biopsies
compared with normal skin (7.9 rank value vs 12.4, respectively),
whereas PDGF-Rβ expression does not show any significant differ-
ence between the groups.
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fields in Figure 2D. Interestingly, proliferation was inversely related
with the expression level of PDGF-Rα as depicted in Figure 2E .
Transfection with the PDGF-Rα plasmid inhibited the proliferation
of two additional human metastatic melanoma cell lines (397 MEL
and A375-S2) as well (Figure 2F ).
These in vitro experiments indicated that PDGF-Rα mediates a
strong antiproliferative effect in different human melanoma cell lines.
Procaspase 3 Levels and Apoptosis Induction in Melanoma
Cells Overexpressing PDGF-Rα
Data reported in Figure 2 suggested that triggering PDGF-Rα
with its selective ligand PDGF-AA, or overexpressing PDGF-Rα,
induce a marked antiproliferation effect. Figure 3A indicates that
SK-MEL-110 cells transfected with PDGF-Rα plasmid show a sig-
nificant reduction in the protein level of procaspase 3, compared
with controls, suggesting activation of the apoptosis cascade. Accord-
ing to this hypothesis, TUNEL staining was found in approximately
20% of adherent cells transfected with PDGF-Rα plasmid, whereas
it was undetectable in control cells (pcDNA3-transfected cells). Rep-
resentative fields are reported in Figure 3B. Propidium iodide incor-
poration experiments indicated that PDGF-Rα overexpression also
increases the percentage of cells in sub-G1 phase (Figure W1A).
The effect onto apoptosis levels was further confirmed in the experi-
ments depicted in Figure 6A.
Additional experiments revealed that the antimitogenic effect of
PDGF-Rα overexpression is abolished by a specific antibody neutral-
izing PDGF-AA or by a soluble recombinant PDGF-Rα (srPDGF-
Rα) that blocks PDGF-Rα or by z-DEVD-FMK blocking procaspase
3 activation (Figure 3C). These data further confirmed that PDGF-Rα
inhibits SK-MEL-110 growth with a PDGF-AA–dependent mecha-
nism and a procaspase 3–dependent apoptosis mechanism.
PDGF-Rα Mediates Staurosporine Toxicity
A number of clinical studies indicate a possible effect of stau-
rosporine derivatives in solid tumors, at least in mouse [29,30].
Staurosporine induces apoptosis in melanoma [31] and increases
PDGF-Rα expression in myofibroblast [32]. We therefore investi-
gated whether staurosporine cytotoxicity may be associated with
PDGF-Rα expression in wild type (i.e., untransfected) melanoma
cells. Staurosporine treatment (50 nM) led to a significant increase
Figure 3. Procaspase 3 protein expression, apoptosis analysis, and PDGF-AA involvement in SK-MEL-110 overexpressing PDGF-Rα. (A)
Procaspase 3 protein level was analyzed by Western blot. PDGF-Rα transfection significantly reduced procaspase 3 protein level after
24 hours of culture. *P < .05 versus pcDNA3-transfected cells. β-Actin was detected to determine protein loading. Bars indicate report
mean ± SD of three experiments; one representative blot is shown below the bar graphs. (B) Apoptosis of adherent cells transfected
with PDGF-Rα after 24 hours of growth. TUNEL staining indicates apoptotic nuclei (arrows) compared with all cells in the field (Hoechst
staining). Three fields of cells transfected with PDGF-Rα and one field of control cells are reported. (C) Proliferation of cells transfected
with PDGF-Rα plasmid. In the presence of neutralizing antibody to PDGF-AA (AbPDGF-AA) or a srPDGF-Rα or a caspase 3 inhibitor (z-DEVD-
FMK), inhibition was completely abolished. Data are mean ± SD of a least three experiments. *P < .05 versus pcDNA3-transfected cells
(100% = 385 × 103).
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in PDGF-Rα protein levels in a time-dependent manner (Figure 4, A
and B, upper). Under such conditions, staurosporine antimitogenic
activity followed similar kinetics (Figure 4B, bottom). PDGF-Rα im-
pairment achieved by treatment with srPDGF-Rα or by transfection
with DN-PDGF-Rα significantly reduced staurosporine’s effect
(Figures 4C and 3D, respectively), confirming the hypothesis that
staurosporine’s toxic effects are mediated, at least in part, by PDGF-Rα.
Infection of Melanoma Cells with AdCMV.PDGF-Rα
A recombinant adenoviral vector was generated, expressing EGFP
and human PDGF-Rα (AdCMV.PDGF-Rα), to induce an efficient
and long-lasting expression of the human PDGF-Rα gene. A control
adenovirus expressing EGFP only was also generated (AdCMV.
EGFP). Cells’ transduction achieved an overexpression of at least
10-fold versus controls in all cases (Figure 7); transduction efficiency
was at least 65% in all experiments. Time course proliferation experi-
ments carried out in vitro indicated that infection with 30 MOI of
AdCMV.PDGF-Rα markedly reduced or almost abolished prolifera-
tion in a dose- and time-dependent way (Figure 5, A and B).
Mechanisms Triggered by Infection with AdCMV.PDGF-Rα
Cell cycle distribution in cells infected with the AdCMV.PDGF-
Rα was monitored by a 10-minute BrdU pulse followed by bivariate
FACS analysis of cells stained with PI. DNA synthesis was found to
be markedly reduced in PDGF-Rα overexpressing cells compared
with control (AdCMV.EGFP–infected cells; 7.4 ± 2.2% vs 20.4 ±
2.3%, respectively, after a 48-hour culture, from three independent
experiments). Figure 6A shows one representative experiment: top of
the figure reports the BrdU incorporation; bottom of the figure shows
alteration of cell cycle distribution and increased sub-G1 population.
According to the results reported in Figure 3B, cells infected with the
AdCMV.PDGF-Rα showed a strong increase in the sub-G1 popu-
lation, that is, 14.1 ± 0.35% in AdCMV.PDGF-Rα–infected cells
versus 0.99 ± 0.27% in AdCMV.EGFP–infected cells (Figure W1B).
pRb plays a role in S-phase arrest induced by cytotoxic agents
[20,33] and acts as growth suppressor in its hypophosphorylated
form [34]. We thus investigated whether PDGF-Rα controls pRb
phosphorylation. Two different antibodies, recognizing either all
pRb forms or pRb in its hypophosphorylated form only, were used
in Western blot analyses. pRb was found mostly in its hyperphos-
phorylated form in control cells (uninfected and AdCMV.EGFP–
infected cells; Figure 6B, lanes 1b and 2b), whereas a faster migrating
hypophosphorylated form appeared in cells overexpressing PDGF-
Rα (lane 3b) after 48 hours of proliferation. The presence of the
pRb hypophosphorylated form was further confirmed using an anti-
body able to specifically recognize pRb in its hypophosphorylated
form (lane 3c).
Figure 4. Staurosporine upregulates PDGF-Rα expression in human melanoma cells. (A) SK-MEL-110 cells exposed to 50 nM stau-
rosporine in 10% FCS for 18 hours show increased PDGF-Rα protein expression by Western blot analysis. β-Actin was detected to
determine the protein loading. Representative experiment. (B) Top: Staurosporine (50 nM) induced a time-dependent increase of
PDGF-Rα protein expression. Data are reported as mean ± SD of three experiments. *P< .05 versus time 0. Bottom: One representative
image of cells treated with 50 nM staurosporine at 0, 6, and 18 hours in 10% FCS. (C) The 10% FCS–induced proliferation in the pres-
ence of staurosporine (0-50 nM). In the presence of srPDGF-Rα, staurosporine cytotoxicity was always significantly reduced. *P < .05,
white bar versus black bar (100% = 540 × 103 and 382 × 103, white bar and black bar respectively). Data are reported as mean ± SD of
three experiments. (D) The 10% FCS–induced proliferation was measured in the presence of staurosporine, in pcDNA3- or DN-PDGF-
Rα–transfected SK-MEL-110. Staurosporine-induced cytotoxicity was significantly reverted in DN-PDGF-Rα–overexpressing cells. **P <
.001, white bar versus black bar (100% = 247 × 103). Data are reported as mean ± SD of three experiments.
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All together, these data indicated that PDGF-Rα overexpression in-
duces apoptosis, markedDNA synthesis inhibition, cell cycle alteration,
and pRb dephosphorylation, explaining at least in part the observed
strong antiproliferative effects.
Molecular Pathways Triggered by PDGF-Rα Overexpression
in Melanoma Cells
At least in some cases, melanoma is known to show increased ex-
pression levels of MAPK/extracellular regulated kinase (ERK)/JUN
signaling pathway members [35] underlying the role MAPK pathway
may play in melanoma biology. We therefore investigated, through a
protein array–based analysis, the expression of 77 members of the
MAPKs pathway in melanoma cells overexpressing PDGF-Rα. The
analysis revealed a number of proteins downregulated or upregulated
in their expression or phosphorylation status. Namely, phosphoryla-
tion of c-Jun at serine 63 ( Jun-pS63) and expression of serine/threo-
nine protein phosphatase 2A/B α (PP2A/Bα) isoform were reduced
more than two-fold versus control (Figure 7, left-hand side). Less
marked down-regulation of other serine/threonine protein phospha-
tases’ subunits was also observed. On the contrary, expression of
p38γ (stress-activated protein kinase 3, SAPK3) isoform was increased
more than three-fold versus control as well as its upstream kinase
MAPK kinase 3 (MKK3) and signal regulatory protein α1 (SIRPα1;
Figure 7, right-hand side). The expression of other members of the
MAPK cascade (i.e., ERK1/2, MEKK4, MAPKK, ERK5, MKK4,
MEK, SOS) was not modified. Down-regulation of Jun-pS63 and
PP2A/Bα and up-regulation of p38γ and SIRPα1 were then con-
firmed in a separate Western blot analysis (Figure 7).
Inhibition of Melanoma Growth In Vivo
Such data provided the rationale and mechanistic insights to hypoth-
esize that PDGF-Rα may interfere with melanoma growth in vivo.
This hypothesis was then tested in a mouse model of primary mela-
noma growth: in three independent experiments, 17 mice (C57BL/6)
were injected with mouse melanoma cells (B16F10) infected with
AdCMV.PDGF-Rα (100 MOI) and 17 mice were injected with
B16F10 infected with AdCMV.EGFP (100 MOI) as control. Tumors
derived from cells infected with AdCMV.PDGF-Rα were markedly
smaller in size and weight (P < .001) compared with control tumors
(Figure 8A). The histologic analysis, performed by CD31 staining, re-
vealed a strongly reduced angiogenesis, with a capillary density lowered
by at last four-fold (Figure 8B); factor VIII staining confirmed these
results. This strong effect was confirmed in separate experiments by
Figure 5. Proliferation of SK-MEL-110 infected with Ad-vector cod-
ing for PDGF-Rα. (A) Proliferation of SK-MEL-110 infected with
30 MOI of AdCMV.PDGF-Rα; uninfected cells and AdCMV.EGFP-
infected cells were used as control. The 10% FCS–induced prolif-
eration at 24, 48, and 72 hours was almost completely inhibited
in AdCMV.PDGF-Rα–infected cells. *P < .05, **P < .01, versus
AdCMV.EGFP (cell number at T = 0 corresponds to 13 × 105).
Data are reported as mean ± SD of three experiments. (B) Dose-
dependent effects of 10, 30, and 100 MOI AdCMV.PDGF-Rα infec-
tion; 10% FCS–induced proliferation at 48 hours. *P < .05, **P <
.01 versus AdCMV.EGFP (cell number at T = 0 corresponds to 13 ×
105). Data are reported as mean ± SD of three experiments.
Figure 6. FACS analysis. (A) At 48 hours after AdCMV.PDGF-Rα
infection, DNA synthesis is markedly inhibited. A representative im-
age of BrdU incorporation (top) and PI staining (bottom) is shown.
(B) SK-MEL-110–uninfected cells (WT) or cells infected with
AdCMV.PDGF-Rα or with AdCMV.EGFP were immunoblotted with
antibodies to pan-pRb, hypophosphorylated pRb (pRb deph), PDGF-
Rα, and tubulin. Cells infected with AdCMV.PDGF-Rα show evident
pRb hypophosphorylation (lanes 3b and 3c).
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in vivo local injection of AdCMV.PDGF-Rα or AdCMV.EGFP (4.5 ×
108 PFU/ml each) as reported in the Materials and methods section.
Four days after injection of normal (i.e., uninfected) melanoma B16F10
cells, 14 mice were treated with local injection of AdCMV.PDGF-Rα
in the site of the primary tumor, and a significant reduction of the
tumor weight was observed after ten additional days (35% inhibi-
tion vs control, P < .05) compared with 14 mice locally injected with
AdCMV.EGFP (Figure 8C ).
These data indicated that melanoma tumors overexpressing PDGF-
Rα show a significantly marked growth inhibition in experiments with
either ex vivo or in vivo treatment.
Discussion
The present study addressed the novel hypothesis that PDGF-Rα
may have autocrine inhibitory control on melanoma growth. Such
hypothesis derives from several considerations: 1) we previously
showed that PDGF-AA and its unique receptor PDGF-Rα exerts a
direct antiangiogenic role in vitro and in vivo [10,12], as opposed to
the stimulatory role of PDGF-BB and PDGF-Rβ; 2) other authors
reported dual opposing effects of PDGF-Rα and PDGF-Rβ in dif-
ferent cell types [7,8,11,36]; 3) proapoptotic activity of PDGF-AA,
the selective ligand of PDGF-Rα, has been reported [37], and a spe-
cific down-regulation of PDGF-Rα is necessary to allow in vitro
growth of human mesothelioma cells [36]; 4) nitric oxide induces
apoptosis, and PDGF-Rα is upregulated by nitric oxide donor treat-
ment in renal mesangial cells [38]; 5) interleukin (IL) 1β and stau-
rosporine, known apoptosis inducers in different cell types including
melanoma [39], upregulate PDGF-Rα expression [32], suggesting
that PDGF-Rα mediates, at least in part, the apoptotic response to
these factors; 6) PDGF-Rα gene belongs to the growth arrest–specific
(gas) gene family [40]; and 7) data presented in the current study and
by others [14] show that expression of PDGF-Rα is reduced in mel-
anoma compared with normal skin or benign nevi, explaining at least
in part why treatment with specific inhibitors of PDGF receptors
does not achieve relevant clinical effects in melanoma patients [15]
and raising questions on the actual role PDGF receptors play in the
control of melanoma progression.
According to these considerations, we hypothesized that melanoma
cells expressing low levels of PDGF-Rα may sustain melanoma pro-
gression, whereas increased PDGF-Rα may inhibit melanoma.
In the present study, we show that overexpressing PDGF-Rα
strongly affects proliferation of four different melanoma cell lines:
human SK-MEL-110, A375, 397, and mouse B16. Data reported
in the literature indicate A375 and 397 harboring BRAF mutations
[41,42], whereas SK-MEL-110 are reported to have wild-type BRAF
and wild-type NRAS [43]. Given the effect observed on all tested cell
lines, the observed PDGF-Rα–dependent inhibition is more likely
to be BRAF/NRAS mutation–independent. PDGF-Rα–forced ex-
pression markedly inhibited melanoma growth and associated with
procaspase 3 reduction, apoptosis, S-phase reduction, and pRb de-
phosphorylation. The antiproliferation effect of PDGF-Rα was com-
pletely abolished when PDGF-AA or PDGF-Rα was neutralized or
when in the presence of caspase 3 inhibitor, further indicating that
PDGF-Rα signaling mediates specific inhibitory/apoptotic stimuli in
melanoma cells’ growth. Staurosporine derivatives such as UCN-01
have shown to potentiate cisplatin anticancer activity and some effect
in melanoma patients [44] and in other solid tumors [45]. Hence,
the findings that staurosporine modulates PDGF-Rα expression
and requires active PDGF-Rα may suggest new ways to increase
its clinical efficacy.
The MAPK pathway consists of ERK, Jun N-terminal kinase
( JNK), and p38 cascades. The ERK activity is generally required
for cell proliferation and transformation, whereas JNK and p38 path-
ways are involved in stress response. In the present study, the expres-
sion level of p38γ (SAPK3) as well as its upstream activator MKK3
(SKK2) were found to be strongly increased in melanoma cells over-
expressing PDGF-Rα. p38 mediates melanoma cells death upon nitric
oxide donor treatment [46], and p38γ isoform is specifically implicated
in melanoma death induced by UV radiation, cisplatin treatment [47],
and γ-irradiation–induced cell cycle arrest [48]. The finding that
PDGF-Rα overexpression increases p38γ led us to hypothesize that
PDGF-Rα in melanoma cells may mediate stressing stimuli leading
to growth inhibition, through up-regulation of p38γ and its upstream
activator MKK3.
SIRPα1 was also strongly upregulated in melanoma cells over-
expressing PDGF-Rα; this was a novel but not surprising finding
because SIRPα1 is known to inhibit growth factor–induced cell pro-
liferation, to be activated by PDGF [49], and to exert tumor suppres-
sor activity [50].
c-Jun mediates the transcription response to growth factor and
stress, and its selective inhibition has shown promise as antitumor
strategy [51]. The concomitant up-regulation of p38γ and down-
regulation of c-Jun phosphorylation observed in melanoma cells
overexpressing PDGF-Rα may thus represent the signal on different
Figure 7. Mitogen-activated protein pathway analysis by protein
array. The expression level of 77 members of the MAPK pathway
was analyzed and expressed as ratio of cells infected with PDGF-
Rα virus versus cells infected with EGFP virus. The insets show val-
idation byWestern blot analysis. The proteins circled, showing a fold
increase or a fold decrease above or below the threshold, respec-
tively, are as follows: 1) phospho c-JUN (pS63); 2) serine/threonine
PP2A/Bα; 75) p38 MAPK, nonactivated clone P38-YNP; 76) SIRPα1,
MKK3 (SAPKK2, SKK2, MEK3); 77) p38γ (SAPK3). The complete
list of proteins numbered from 1 to 77 in the graph is reported as
a Supplemental Information. Data are reported as mean ± SD of
three experiments.
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arms of the MAPK pathway, triggering, at least in part, the observed
inhibitory effects. Moreover, phosphatase activities are crucial to
control protein activation. PP2A is a key multimeric serine/threonine
phosphatase. Expression of its B-subunit isoform α was found to be
markedly reduced in melanoma cells overexpressing PDGF-Rα, sug-
gesting that, under such conditions, specific substrates of PP2A may
not be recognized.
Melanoma is a poor-prognosis cancer in its metastatic phase. Spe-
cific tyrosine kinase inhibitors and other receptor inhibitors represent
novel promising clinical approaches, with still controversial effects.
Although the monoclonal antibody neutralizing vascular endothelial
growth factor receptor (bevacizumab) shows some clinical promise,
the simultaneous inhibition of PDGF-Rα and PDGF-Rβ has not
shown clinical benefit in melanoma [15,52]. These findings raise
intriguing questions on the actual role these receptors play in mela-
noma and may suggest new therapeutic approaches effective at the
clinical level. In vivo analyses carried out in the present study show
that melanoma cells overexpressing PDGF-Rα give rise to tumors
markedly smaller in weight and with strongly reduced tumor an-
giogenesis compared with controls. We speculate that the observed
in vivo antitumor effect likely derives from the combination of a
direct antimitogenic and proapoptotic action on tumor cells on
one side and an antiangiogenic activity on the other, likely related
to the sequestration of PDGF-Rα ligands. A recently published re-
port found the promitogenic effects of PDGF-CC in melanoma, me-
diated by PDGF-Rα, through paracrine effects onto fibroblasts and
other cell types [53]. All together, these data confirm the different
autocrine and paracrine effects of PDGF-Rα.
In conclusion, the current study indicates for the first time a novel
role of PDGF-Rα in controlling melanoma cell proliferation and
may help understand the mechanisms underlying melanoma’s ability
to evade apoptosis and drug-induced toxicity.
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Supplemental Information
The complete list of proteins numbered from 1 to 77 in the graph
of Figure 7 is the following (see also antibody list at: http://www.
sigmaaldrich.com/etc/medialib/docs/Sigma-Aldrich/Bulletin/
mpaa3antibodylist.Par.0001.File.tmp/mpaa3antibodylist.pdf ): 1)
phospho c-JUN (pS63); 2) serine/threonine PP2A/Bα; 3) serine/
threonine PP2A/B′ pan 2; 4) serine/threonine PP2A/Bγ; 5) serine/
threonine protein phosphatase 1γ1; 6) serine/threonine protein
phosphatase 2Cα/β; 7) c-erbB-4 cl.HER4-36; 8) serine/threonine
protein phosphatase 1/β; 9) c-erbB-3 cl.RTJ1; 10) serine/threonine
PP2A/A; 11) MAPK, activated (diphosphorylated ERK-1 and 2) cl.
MAPK-YT; 12) protein kinase Cβ1 cl.PK-B13; 13) MAPK (ERK-1,
ERK-2); 14) p38 MAPK, activated diphosphorylated p38 clone
P38-TY; 15) c-Jun N-terminal kinase ( JNK1, JNK2); 16) vascular
endothelial growth factor receptor 1; 17) S6 kinase; 18) MAPK, non-
phosphorylated ERK cl.ERK-NP2; 19) c-erbB-2 clone HER2-96;
20) MEKK4 clone MEKK4-338; 21) phosphotyrosine clone pT-
154; 22) protein kinase Cα; 23) MAPK kinase (MEK, MAPKK);
24) MAPK, monophosphorylated threonine clone ERK-YNP; 25)
Ap-1; 26) MCL-1; 27) phosphatidylinositol 3-kinase (PI3-K, p85α);
28) phosphothreonine clone PTR-8; 29) MAPK kinase 4 (MKK4,
SEK1, JNKK1); 30) protein tyrosine phosphatase PEST clone AG25;
31) MAPK, monophosphorylated tyrosine clone ERK-PY193; 32)
JNK, activated (diphosphorylated JNK) clone JNK-PT48; 33) Crk-L;
34) GAPDH clone GAPDH-71.1; 35) CRK-II; 36) ATF2; 37) phos-
phoserine clone PSR-45; 38)MAPK phosphatase 1 (MKP-1); 39) Sos1;
40) protein kinase Cγ clone PK-G4; 41) P130cas; 42) protein kinaseCδ;
43)MAPK (ERK-1); 44)MAPK, activated/monophosphorylated (phos-
phothreonine ERK-1 and 2) clone ERK-PT115; 45) c-CBL; 46)MAPK
activated protein kinase 2 (MAKAPK2); 47) RSK1; 48) p38 MAPK;
49) protein phosphatase 1α; 50) estrogen receptor; 51) ERK5 (big
MAPK, BMK1); 52) KSR clone C3H7D2; 53) ATF 1; 54) protein
kinase Cβ1; 55) phospho ATF 2 (pThr69,71) clone ATF-22P; 56)
SH-PTP2 (SHP-2); 57) ILK; 58) Grb-2 clone GRB-232; 59) RAF1;
60) phospholipase Cγ1 (PLCγ1); 61) RAF1 clone RNP1; 62) protein
kinase Cβ2 clone PK-B26; 63) protein kinase Cɛ; 64) ILK clone 65; 65)
epidermal growth factor receptor clone F4; 66) protein kinaseC cl.MC5;
67) phospholipase A2; 68) secretory group V cl.MCL-3G1; 69) phos-
pho c-JUN (pS73); 70) protein kinase Cβ2; 71) protein kinase Cζ; 72)
MAPK 2 (ERK-2) clone: 1B3B9; 73) protein kinase Cη; 74) protein
kinase Cγ; 75) p38MAPK, nonactivated clone P38-YNP; 76) SIRPα1,
MKK3 (SAPKK2, SKK2, MEK3); and 77) p38γ (SAPK3).
Figure W1. Propidium iodide incorporation analyzed by FACS analysis, in SK-MEL-110 cells transfected with pcDNA3 or PDGF-Rα plas-
mid (A) or infected with AdCMV.EGFP or AdCMV.PDGF-Rα (B).
